Liquidia Corporation Announces First Research & Development Day Focusing on Innovative Therapies for Pulmonary Hypertension

Liquidia Corporation will host a webcast R&D Day on October 28, 2025, discussing treatments for pulmonary hypertension.

Quiver AI Summary

Liquidia Corporation announced it will host its first Research & Development Day on October 28, 2025, in New York City, which will also be available via live webcast. The event will feature presentations from Liquidia’s management and key opinion leaders in pulmonary arterial hypertension (PAH) and associated conditions, focusing on their investigational product L606, a sustained-release formulation of treprostinil, and providing updates on their approved product YUTREPIA, an inhalation powder for treating PAH and pulmonary hypertension related to interstitial lung disease. The R&D Day aims to highlight Liquidia’s progress and opportunities to enhance patient outcomes. Institutional investors and analysts are invited to attend, with registration details provided for both in-person attendance and online access.

Potential Positives

Liquidia Corporation is hosting its first Research & Development Day, showcasing its commitment to transparency and engagement with institutional investors and analysts.
The event will feature key presentations on L606 and YUTREPIA™, highlighting Liquidia's innovative approaches in treating pulmonary arterial hypertension and interstitial lung disease.
Involvement of key opinion leaders in the field enhances the credibility of Liquidia's research and development efforts, potentially attracting more attention from the medical community and investors.
The archived webcast of the event will ensure ongoing accessibility to information, furthering engagement with stakeholders beyond the live presentation.

Potential Negatives

Liquidia's R&D Day is primarily aimed at institutional investors and sell-side analysts, which may limit engagement with the broader patient community and other stakeholders.
The mention of investigational products, including L606, suggests that Liquidia is still in early stages of development and may face uncertainties regarding regulatory approval timelines and efficacy.
Highlighting that L606 is still being evaluated in an open-label study may raise concerns about the lack of definitive clinical results to support its commercial viability.

FAQ

What is the purpose of Liquidia's R&D Day?

The R&D Day aims to showcase Liquidia's advancements in therapies for PAH and PH-ILD, featuring expert presentations.

When and where will Liquidia's R&D Day be held?

The event will take place on October 28, 2025, in New York City from 2:00 p.m. to 4:30 p.m. EST.

How can I participate in Liquidia's R&D Day?

Institutional investors and analysts can RSVP to attend in person or register for the live webcast on Liquidia's website.

What products are highlighted during the R&D Day?

The event will feature L606, an investigational treprostinil formulation, and YUTREPIA™, Liquidia's inhalation powder for PAH and PH-ILD.

What is L606 and its significance?

L606 is an investigational sustained-release formulation of treprostinil, designed to enhance drug delivery for treating pulmonary hypertension.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$LQDA Insider Trading Activity

$LQDA insiders have traded $LQDA stock on the open market 47 times in the past 6 months. Of those trades, 0 have been purchases and 47 have been sales.

Here’s a breakdown of recent trading of $LQDA stock by insiders over the last 6 months:

PAUL B MANNING has made 0 purchases and 4 sales selling 670,837 shares for an estimated $18,957,475.
SCOTT MOOMAW (Chief Commercial Officer) has made 0 purchases and 7 sales selling 86,132 shares for an estimated $2,261,069.
MICHAEL KASETA (CFO and COO) has made 0 purchases and 6 sales selling 85,499 shares for an estimated $1,666,714.
RAMAN SINGH has made 0 purchases and 2 sales selling 53,024 shares for an estimated $1,395,624.
ROGER JEFFS (Chief Executive Officer) has made 0 purchases and 4 sales selling 85,244 shares for an estimated $1,289,592.
JASON ADAIR (Chief Business Officer) has made 0 purchases and 8 sales selling 35,897 shares for an estimated $884,868.
RAJEEV SAGGAR (Chief Medical Officer) has made 0 purchases and 6 sales selling 41,614 shares for an estimated $882,681.
RUSSELL SCHUNDLER (General Counsel) has made 0 purchases and 5 sales selling 24,246 shares for an estimated $382,726.
JOANNA HOROBIN sold 5,000 shares for an estimated $135,850
SARAH KREPP (Chief Human Resource Officer) has made 0 purchases and 2 sales selling 2,882 shares for an estimated $44,241.
DANA BOYLE (Chief Accounting Officer) has made 0 purchases and 2 sales selling 2,256 shares for an estimated $37,807.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$LQDA Hedge Fund Activity

We have seen 102 institutional investors add shares of $LQDA stock to their portfolio, and 82 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DEERFIELD MANAGEMENT COMPANY, L.P. added 1,616,778 shares (+inf%) to their portfolio in Q2 2025, for an estimated $20,145,053
GOLDMAN SACHS GROUP INC added 1,555,774 shares (+180.6%) to their portfolio in Q2 2025, for an estimated $19,384,944
TYRO CAPITAL MANAGEMENT LLC added 1,241,839 shares (+inf%) to their portfolio in Q2 2025, for an estimated $15,473,313
VESTAL POINT CAPITAL, LP removed 1,227,403 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $15,293,441
CENTERBOOK PARTNERS LP added 982,778 shares (+811.7%) to their portfolio in Q2 2025, for an estimated $12,245,413
SHAY CAPITAL LLC added 705,758 shares (+inf%) to their portfolio in Q2 2025, for an estimated $8,793,744
INVESCO LTD. removed 614,407 shares (-94.7%) from their portfolio in Q2 2025, for an estimated $7,655,511

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$LQDA Analyst Ratings

Wall Street analysts have issued reports on $LQDA in the last several months. We have seen 7 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 10/06/2025
Jefferies issued a "Buy" rating on 08/15/2025
Needham issued a "Buy" rating on 08/12/2025
Wells Fargo issued a "Overweight" rating on 06/12/2025
B of A Securities issued a "Buy" rating on 06/11/2025
Scotiabank issued a "Sector Outperform" rating on 05/28/2025
Oppenheimer issued a "Underperform" rating on 05/19/2025

To track analyst ratings and price targets for $LQDA, check out Quiver Quantitative's $LQDA forecast page.

$LQDA Price Targets

Multiple analysts have issued price targets for $LQDA recently. We have seen 9 analysts offer price targets for $LQDA in the last 6 months, with a median target of $35.0.

Here are some recent targets:

Andrew S. Fein from HC Wainwright & Co. set a target price of $35.0 on 10/06/2025
Amy Li from Jefferies set a target price of $43.0 on 08/15/2025
Ryan Deschner from Raymond James set a target price of $41.0 on 08/13/2025
Tiago Fauth from Wells Fargo set a target price of $31.0 on 08/13/2025
Serge Belanger from Needham set a target price of $36.0 on 08/12/2025
Jason Gerberry from B of A Securities set a target price of $23.0 on 06/11/2025
Greg Harrison from Scotiabank set a target price of $37.0 on 05/28/2025

Full Release

MORRISVILLE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that it will host a Research & Development Day (R&D Day) on Tuesday, October 28, 2025, in New York City which will be webcast from 2:00 p.m. to 4:30 p.m. Eastern Standard Time.

The event will feature presentations from Liquidia’s management team alongside three key opinion leaders (KOLs) in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The agenda will focus on L606 (treprostinil liposome inhalation suspension), an investigational sustained-release formulation, and include a clinical update on its flagship product, YUTREPIA™ (treprostinil) inhalation powder. All presenters will be available to answer questions at the end of the programmed portion of the presentation.

Roger Jeffs, Chief Executive Officer of Liquidia, said: ”Our first R&D Day represents an important milestone as we bring together our team with recognized experts in the fields of PAH and PH-ILD to highlight the opportunities to improve patient outcomes and the significant progress Liquidia has made.”

Liquidia’s R&D Day is intended for institutional investors and sell-side analysts. To attend in person, please RSVP by clicking here , as space is limited. To register for the live webcast, please click here .

The live webcast of the event and accompanying presentation materials will be accessible through the Events & Presentations page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations . An archived, recorded version of the presentation will be available on Liquidia’s website following the event.

About L606 (treprostinil liposome inhalation suspension)
L606 is an investigational, sustained-release formulation of treprostinil administered twice daily through rapid nebulization with a hand-held portable system. The L606 suspension uses Pharmosa Biopharm’s proprietary liposomal formulation to encapsulate treprostinil which can be released slowly at a controlled rate into the lung, enhancing drug exposure over an extended period of time. L606 is currently being evaluated in an open-label study in the United States for treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) with a planned global, pivotal, randomized, placebo-controlled study for the treatment of PH-ILD.

About YUTREPIA™ (treprostinil) Inhalation Powder
YUTREPIA is an inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. YUTREPIA is indicated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. YUTREPIA was previously referred to as LIQ861 in investigational studies.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT Technology. PRINT enabled the creation of Liquidia’s first approved product, YUTREPIA (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606 (treprostinil liposome inhalation suspension), an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets Treprostinil Injection, the first-to-file, fully substitutable generic of Remodulin, for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com .

Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
[email protected]

Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
[email protected]